France Analysis

Pages

Industry Trend Analysis - Sanofi/WRAIR Deal Heightens Argument Around US Investment - JULY 2017

The ongoing debate around the Zika vaccine deal between the US Army and Sanofi is set to continue throughout the R&D process. There is little interest for pharmaceutical companies to spend a large amount of money on developing a novel vaccine and there is risk to these not being profitable. If there are changes in the future licensing deals, due to ongoing controversy, this will...

READ FULL ARTICLE

Pages